TriSalus Life Sciences

TriSalus Life Sciences, Inc. is an oncology company, which engages in the business of integrating standard-of-care treatments and investigational immunotherapeutic with disruptive pressure enabled drug delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. The company is headquartered in Westminster, Colorado and currently employs 102 full-time employees. The company went IPO on 2020-12-18. The company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technological applications. Its delivery method, Pressure-Enabled Drug Delivery (PEDD), modulates pressure and flow within blood vessels to improve intravascular therapeutic delivery into tumors, thereby increasing the likelihood of tumor response in comparison to conventional delivery technologies. Its on-market TriNav Infusion System using PEDD technology, is being used for interventional radiology procedures, commonly transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or in patients with liver metastases. TriNav is a device with a novel (PEDD) delivery method.